© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Vigil Neuroscience, Inc. (VIGL) stock surged +15.76%, trading at $2.35 on NASDAQ, up from the previous close of $2.03. The stock opened at $2.29, fluctuating between $2.04 and $2.94 in the recent session.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Employees | 64 |
Beta | 1.93 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Vigil Neuroscience, Inc. (NASDAQ: VIGL) stock price is $2.35 in the last trading session. During the trading session, VIGL stock reached the peak price of $2.94 while $2.04 was the lowest point it dropped to. The percentage change in VIGL stock occurred in the recent session was 15.76% while the dollar amount for the price change in VIGL stock was $0.32.
The NASDAQ listed VIGL is part of Biotechnology industry that operates in the broader Healthcare sector. Vigil Neuroscience, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Charles Maggs
Head of FP&A
Kelly Neelon Ph.D.
Vice President of CMC & Technical Operations
Christian Mirescu Ph.D.
Vice President & Head of Neuroimmunology
Ms. Jennifer Ziolkowski CPA, CPA
Chief Financial Officer
Mr. Evan A. Thackaberry DABT, Ph.D.
Senior Vice President & Head of Early Devel.
Ms. Sarah Carmody
Vice President of Investor Relations & Corporation Communications
Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
Pres, Chief Executive Officer & Director
Park Guo CPA
Accounting Mang.
Weeteck Yeo Ph.D.
Senior Vice President of Strategic Operations
Mr. Christopher Verni J.D.
Gen. Counsel & Corporation Sec.
Dr. David Gray Ph.D.
Chief Scientific Officer
April Effort M.B.A., M.S.
Vice President & Head of Corporation Devel.
VIGL's closing price is 57.72% higher than its 52-week low of $1.49 where as its distance from 52-week high of $6.06 is -61.22%.
Number of VIGL employees currently stands at 64.
Official Website of VIGL is: https://www.vigilneuro.com
VIGL could be contacted at phone 857 254 4445 and can also be accessed through its website. VIGL operates from 1 Broadway, Cambridge, MA 02142, United States.
VIGL stock volume for the day was 42.04M shares. The average number of VIGL shares traded daily for last 3 months was 233.04K.
The market value of VIGL currently stands at $96.07M with its latest stock price at $2.35 and 40.88M of its shares outstanding.